HOOKIPA Doses First Patient in Hepatitis B Clinical Trial

HOOKIPA Pharma, Inc. (Nasdaq: HOOK) has dosed the first patient in a clinical trial collaboration with Gilead for a treatment for Hepatitis B.

HOOKIPA’s HB-400 is an investigational therapeutic vaccine for chronic hepatitis B and one of two novel compounds being developed in collaboration with Gilead (Nasdaq: GILD).


The Phase 1 clinical trial (NCT05770895) aims to evaluate the safety and tolerability of repeated doses of HB-400 in healthy participants and participants with chronic hepatitis B.HOOKIPA earned a $5 million non-dilutive payment from Gilead under its collaboration agreement in January 2023.HOOKIPA is working on two independent development programs in collaboration with Gilead. The second program is the development of a novel arenaviral vaccine as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).


HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Share This Article


About the Author

HOOKIPA Doses First Patient in Hepatitis B Clinical Trial

Editor Prism MarketView